ZA201603117B - Withanolides useful for the treatment of neurodegenerative diseases - Google Patents
Withanolides useful for the treatment of neurodegenerative diseasesInfo
- Publication number
- ZA201603117B ZA201603117B ZA2016/03117A ZA201603117A ZA201603117B ZA 201603117 B ZA201603117 B ZA 201603117B ZA 2016/03117 A ZA2016/03117 A ZA 2016/03117A ZA 201603117 A ZA201603117 A ZA 201603117A ZA 201603117 B ZA201603117 B ZA 201603117B
- Authority
- ZA
- South Africa
- Prior art keywords
- withanolides
- useful
- treatment
- neurodegenerative diseases
- neurodegenerative
- Prior art date
Links
- PQZVBIJEPVKNOZ-PCLZMVHQSA-N (2R)-2-[(1S)-1-hydroxy-1-[(5R,6R,8R,9S,10R,13S,14R,17S)-5,6,14,17-tetrahydroxy-10,13-dimethyl-1-oxo-6,7,8,9,11,12,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-yl]ethyl]-4,5-dimethyl-2,3-dihydropyran-6-one Chemical class C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@]1(O)[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=CC[C@]4(O)[C@H](O)C[C@H]3[C@]2(O)CC1 PQZVBIJEPVKNOZ-PCLZMVHQSA-N 0.000 title 1
- JAVFSUSPBIUPLW-QEWGJZFKSA-N Withanolide Natural products O=C1[C@@H](C)[C@H](C)C[C@H]([C@@H](C)[C@@H]2[C@@]3(C)[C@H]([C@@H]4[C@@H]([C@]5(C)[C@@H](CC4)CCCC5)CC3)CC2)O1 JAVFSUSPBIUPLW-QEWGJZFKSA-N 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908455P | 2013-11-25 | 2013-11-25 | |
| PCT/US2014/067436 WO2015077780A1 (en) | 2013-11-25 | 2014-11-25 | Withanolides useful for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201603117B true ZA201603117B (en) | 2020-05-27 |
Family
ID=52023694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/03117A ZA201603117B (en) | 2013-11-25 | 2016-05-10 | Withanolides useful for the treatment of neurodegenerative diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10351590B2 (enExample) |
| EP (1) | EP3074414B1 (enExample) |
| JP (1) | JP6517833B2 (enExample) |
| KR (1) | KR20160137945A (enExample) |
| CN (1) | CN105940010B (enExample) |
| AU (1) | AU2014352629B2 (enExample) |
| BR (1) | BR112016012002A2 (enExample) |
| CA (1) | CA2931064C (enExample) |
| ES (1) | ES2728870T3 (enExample) |
| MX (1) | MX364528B (enExample) |
| PL (1) | PL3074414T3 (enExample) |
| TR (1) | TR201905218T4 (enExample) |
| WO (1) | WO2015077780A1 (enExample) |
| ZA (1) | ZA201603117B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019116069A1 (en) * | 2017-12-11 | 2019-06-20 | Ethnodyne | Compounds for treating neurodegenerative disorders |
| US20210087222A1 (en) * | 2017-12-11 | 2021-03-25 | Ethnodyne | Compounds for treating neurodegenerative disorders |
| EP3724207A1 (en) * | 2017-12-11 | 2020-10-21 | Ethnodyne | Compounds for treating neurodegenerative disorders |
| CN111377994A (zh) * | 2018-12-28 | 2020-07-07 | 南开大学 | 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途 |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CN116063373B (zh) * | 2023-02-14 | 2025-04-15 | 广西医科大学 | 天然产物27-Deoxywithaferin A的制备方法 |
| EP4788688A1 (en) * | 2023-10-03 | 2026-08-12 | Enveda Therapeutics, Inc. | Withaferin a analog and method for treatment using the same |
| CN117924401B (zh) * | 2024-01-22 | 2026-05-12 | 黑龙江中医药大学 | 一种具有神经炎症抑制活性的化合物及其提取方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010030395A2 (en) * | 2008-09-15 | 2010-03-18 | Whitehead Institute For Biomedical Research | Withaferin a analogs and uses thereof |
| WO2010053655A2 (en) | 2008-11-07 | 2010-05-14 | University Of Kansas | Therapeutic methods with withaferin a and analogs |
| US8598339B2 (en) | 2011-02-01 | 2013-12-03 | University Of Kansas | Withanolide isolated from Physalis longifolia and analogs and methods of use thereof |
| ES2679289T3 (es) * | 2011-06-22 | 2018-08-23 | UNIVERSITé LAVAL | Procedimientos para el pronóstico y/o diagnóstico de una enfermedad neurodegenerativa, procedimientos para identificar compuestos candidatos y compuestos para tratar una enfermedad neurodegenerativa |
-
2014
- 2014-11-25 TR TR2019/05218T patent/TR201905218T4/tr unknown
- 2014-11-25 CA CA2931064A patent/CA2931064C/en active Active
- 2014-11-25 JP JP2016554830A patent/JP6517833B2/ja not_active Expired - Fee Related
- 2014-11-25 BR BR112016012002A patent/BR112016012002A2/pt not_active IP Right Cessation
- 2014-11-25 EP EP14812105.6A patent/EP3074414B1/en not_active Not-in-force
- 2014-11-25 MX MX2016006544A patent/MX364528B/es active IP Right Grant
- 2014-11-25 CN CN201480064227.0A patent/CN105940010B/zh not_active Expired - Fee Related
- 2014-11-25 KR KR1020167015115A patent/KR20160137945A/ko not_active Ceased
- 2014-11-25 ES ES14812105T patent/ES2728870T3/es active Active
- 2014-11-25 WO PCT/US2014/067436 patent/WO2015077780A1/en not_active Ceased
- 2014-11-25 AU AU2014352629A patent/AU2014352629B2/en not_active Ceased
- 2014-11-25 PL PL14812105T patent/PL3074414T3/pl unknown
- 2014-11-25 US US15/038,927 patent/US10351590B2/en active Active
-
2016
- 2016-05-10 ZA ZA2016/03117A patent/ZA201603117B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160137945A (ko) | 2016-12-02 |
| EP3074414A1 (en) | 2016-10-05 |
| WO2015077780A1 (en) | 2015-05-28 |
| MX364528B (es) | 2019-04-30 |
| AU2014352629B2 (en) | 2019-03-28 |
| JP6517833B2 (ja) | 2019-05-22 |
| JP2016537432A (ja) | 2016-12-01 |
| MX2016006544A (es) | 2016-12-12 |
| CN105940010B (zh) | 2018-03-30 |
| PL3074414T3 (pl) | 2019-12-31 |
| US10351590B2 (en) | 2019-07-16 |
| CN105940010A (zh) | 2016-09-14 |
| CA2931064A1 (en) | 2015-05-28 |
| CA2931064C (en) | 2022-10-18 |
| EP3074414B1 (en) | 2019-01-09 |
| BR112016012002A2 (pt) | 2017-09-19 |
| US20170022247A1 (en) | 2017-01-26 |
| ES2728870T3 (es) | 2019-10-29 |
| AU2014352629A1 (en) | 2016-05-26 |
| TR201905218T4 (tr) | 2019-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273815B (en) | Secondary vaccine particles for the treatment of inflammation | |
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL243976B (en) | kdm1a inhibitors for disease treatment | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| IL241264A0 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| IL244014A0 (en) | Combined therapy for the treatment of glioblastoma | |
| IL241101B (en) | Medicinal uses of empagliflozin | |
| ZA201505909B (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL241102A0 (en) | Medicinal uses of empagliflozin | |
| SG10201709090UA (en) | Sobetirome in the treatment of myelination diseases | |
| SI2981271T1 (sl) | Terapevtske uporabe empagliflozina | |
| PL3074414T3 (pl) | Witanolidy przydatne do leczenia chorób neurodegeneracyjnych | |
| PL3062790T3 (pl) | Połączenia farmaceutyczne do leczenia raka | |
| IL243637B (en) | PPAR-sparing compounds for the treatment of metabolic diseases | |
| EP3013824B8 (en) | Carboline compounds usable in the treatment of neurodegenerative diseases | |
| ZA201507718B (en) | The local treatment of inflammatory ophthalmic diseases | |
| EP3089984A4 (en) | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | |
| SI2855487T1 (sl) | Spojine za zdravljenje ishemično-reperfuzijsko-povezanih bolezni | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| HK40032828A (en) | Methods for the treatment of mitochondrial disease | |
| HK40009827B (en) | Immune-modifying particles for the treatment of inflammation | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
| GB201321628D0 (en) | Treatment of disease | |
| AU2013904239A0 (en) | Pharmaceutical combinations for the treatment of cancer |